PL437549A1 - Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe - Google Patents

Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe

Info

Publication number
PL437549A1
PL437549A1 PL437549A PL43754921A PL437549A1 PL 437549 A1 PL437549 A1 PL 437549A1 PL 437549 A PL437549 A PL 437549A PL 43754921 A PL43754921 A PL 43754921A PL 437549 A1 PL437549 A1 PL 437549A1
Authority
PL
Poland
Prior art keywords
bacteriophage
prevention
treatment
production
gel
Prior art date
Application number
PL437549A
Other languages
English (en)
Inventor
Jarosław DASTYCH
Ewelina A. WÓJCIK
Agnieszka MASZEWSKA
Marta SZYMAŃSKA
Przemysław SZEWCZYK
Elżbieta GÓRECKA
Joanna KAZIMIERCZAK
Arkadiusz GUZIŃSKI
Marta KRZYŻANIAK
Daria KRÓLIKOWSKA
Justyna ANDRYSIAK
Paulina WIGNER
Małgorzata STAŃCZYK
Original Assignee
Proteon Pharmaceuticals Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Pharmaceuticals Spółka Akcyjna filed Critical Proteon Pharmaceuticals Spółka Akcyjna
Priority to PL437549A priority Critical patent/PL437549A1/pl
Priority to BR112023021130A priority patent/BR112023021130A2/pt
Priority to AU2022259360A priority patent/AU2022259360A1/en
Priority to CA3215008A priority patent/CA3215008A1/en
Priority to EP22732685.7A priority patent/EP4322966A2/en
Priority to PCT/PL2022/050021 priority patent/WO2022220699A2/en
Publication of PL437549A1 publication Critical patent/PL437549A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, w szczególności wywołanych szczepami E. coli i/lub S. aureus, przeznaczony do podawania dowymieniowo w okresie laktacji lub zasuszenia, zwłaszcza w celu leczenia lub zapobiegania zapaleniu wymienia u bydła mlecznego, sposób jego wytwarzania oraz szczepy bakteriofagowe szczególnie przydatne do wytwarzania takiego preparatu.
PL437549A 2021-04-11 2021-04-11 Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe PL437549A1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL437549A PL437549A1 (pl) 2021-04-11 2021-04-11 Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe
BR112023021130A BR112023021130A2 (pt) 2021-04-11 2022-04-11 Preparação de bacteriófagos em forma de gel para prevenir ou tratar infecções bacterianas em gado leiteiro, seu método de fabricação e cepas de bacteriófagos
AU2022259360A AU2022259360A1 (en) 2021-04-11 2022-04-11 A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, its manufacturing method and bacteriophage strains
CA3215008A CA3215008A1 (en) 2021-04-11 2022-04-11 A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, its manufacturing method and bacteriophage strains
EP22732685.7A EP4322966A2 (en) 2021-04-11 2022-04-11 A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, its manufacturing method and bacteriophage strains
PCT/PL2022/050021 WO2022220699A2 (en) 2021-04-11 2022-04-11 A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, its manufacturing method and bacteriophage strains

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437549A PL437549A1 (pl) 2021-04-11 2021-04-11 Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe

Publications (1)

Publication Number Publication Date
PL437549A1 true PL437549A1 (pl) 2022-10-17

Family

ID=82156757

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437549A PL437549A1 (pl) 2021-04-11 2021-04-11 Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe

Country Status (6)

Country Link
EP (1) EP4322966A2 (pl)
AU (1) AU2022259360A1 (pl)
BR (1) BR112023021130A2 (pl)
CA (1) CA3215008A1 (pl)
PL (1) PL437549A1 (pl)
WO (1) WO2022220699A2 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
US20030235560A1 (en) * 2000-05-12 2003-12-25 Harrison Richard J. Mastitis prevention
US11311582B2 (en) * 2015-11-19 2022-04-26 Locus Biosciences, Inc. Bacteriophage compositions and methods of use thereof
CN111254122B (zh) * 2020-03-12 2021-12-31 青岛诺安百特生物技术有限公司 葡萄球菌噬菌体组合物及其在防治葡萄球菌感染疾病的药物中应用

Also Published As

Publication number Publication date
BR112023021130A2 (pt) 2023-12-19
AU2022259360A1 (en) 2023-11-02
EP4322966A2 (en) 2024-02-21
WO2022220699A3 (en) 2022-11-24
WO2022220699A2 (en) 2022-10-20
CA3215008A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
Meije et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection
BR112015027636A2 (pt) Uso da composição farmacêutica
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
PL437549A1 (pl) Preparat bakteriofagowy w postaci żelu do zapobiegania lub leczenia zakażeń bakteryjnych w hodowlach bydła mlecznego, sposób jego wytwarzania oraz szczepy bakeriofagowe
BR112021021443A2 (pt) Proteína ou fragmento antigênico da mesma, composição, vetor de expressão, pluralidade de células, método, e, artigo de fabricação
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
GEP20197030B (en) Antimicrobial composition against gastrointestinal infections and the use of thereof
Sarker et al. Surgical management of unilateral gangrenous mastitis in a doe: A case report
WO2019234509A3 (en) Aminomethylamidine and methylamidine antimicrobial compounds
LV15071B (lv) Kompozīcija subklīniska mastīta ārstēšanai govīm
GEP20197029B (en) Antimicrobial composition and the use of thereof
Ijaz et al. Treatment of chronic mastitis in a dairy cow: A case report
GB2589856A (en) Composition for use of reducing SCC and subsequent mastitis in dairy cows
BR102017024154A2 (pt) ?segunda pele bovina com propriedades antimicrobiana e biodegradável para proteção do gado leiteiro contra a mastite?
Taemchuay et al. Development of the Centella asiatica crude extracts using DMSO, Tween 20, propylene glycol and tween 80 as solvent solutions for creating teat dips.
Corona et al. In vitro antibacterial efficacy of a based blackcurrant oil shampoo against: Staphylococcus pseudintermedius, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Beccaria et al. Efficacy of Panax ginseng extract combined with cephalexin as a dry cow therapy
Lindgren et al. Eradication of MRSA throat carriage-a randomized trial comparing topical treatment with rifampicin-based systemic therapy
PL439344A1 (pl) Preparat przeciwbakteryjny z biomasy opadłych liści drzew i sposób jego wytwarzania
PL435199A1 (pl) Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli
MX2023011616A (es) Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos.
Kumar et al. Therapeutic management of clinical mastitis in cows
Altan et al. The use of combination of antibiotherapy and dimetylsulphoxide in the treatment of infectious keratoconjunctivitis in calves.
MX2016001161A (es) Composicion veterinaria para uso intramamario e intramuscular en ganado bovino, que comprende una formulacion y proceso de aplicacion a base de nanoparticulas de plata para el tratamiento de mastitis clinica, subclinica y cronica.